Flexion Therapeutics (NASDAQ:FLXN) issued its earnings results on Thursday. The specialty pharmaceutical company reported ($1.00) EPS for the quarter, beating analysts’ consensus estimates of ($1.01) by $0.01, Fidelity Earnings reports. The firm had revenue of $21.79 million for the quarter, compared to the consensus estimate of $18.85 million. Flexion Therapeutics had a negative return on equity of 175.29% and a negative net margin of 368.31%.
Shares of FLXN traded down $0.69 during trading hours on Friday, hitting $16.43. 1,132,400 shares of the company were exchanged, compared to its average volume of 622,178. Flexion Therapeutics has a 52 week low of $8.76 and a 52 week high of $17.82. The company has a market cap of $655.05 million, a PE ratio of -3.66 and a beta of 1.38. The firm’s 50 day moving average is $14.85 and its 200-day moving average is $12.36. The company has a debt-to-equity ratio of 3.95, a quick ratio of 7.33 and a current ratio of 7.80.
Several analysts have recently issued reports on FLXN shares. Zacks Investment Research downgraded Flexion Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 8th. Northland Securities set a $20.00 price target on Flexion Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, September 10th. BidaskClub upgraded Flexion Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, November 5th. Finally, ValuEngine downgraded Flexion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, October 25th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $23.57.
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.
Featured Story: What is a Swap?
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.